Life Sciences

Driving Innovation and Growth in Healthcare

Helping companies and investors capitalise on science and technology innovations


raised since 2022


of all sector activity

Cavendish has the largest healthcare franchise on AIM with 24 retained clients, making up over 35% of all AIM listed healthcare companies *.

We have a wealth of experience across the sector, with three dedicated analysts, specialist sales and a further team of six across ECM and private M&A.  We believe that the breadth and depth of our sector knowledge make us the advisor of choice for any ambitious healthcare business that is looking to drive growth or a potential exit/re-financing.

We are consistently one of the most active advisers in the sector, raising over £105m across 13 secondaries and an IPO in feed additives since early 2022. This represents over 25% of all activity in the life sciences sector where approximately £400m** was raised in 2022/3.  

On the private market side, we have advised on multiple successful sell side mandates including sales to high-profile global multi-nationals as well as to private equity purchasers, with many of our purchasers based overseas.  We have international reach through Oaklins offices worldwide with further specialist sub-sector expertise and local knowledge through these offices.

We believe there are huge opportunities in the both the public and private markets for companies and investors alike to capitalise on the science and technology coming out of the UK aligned with a supportive investor base. There are many reasons to be positive and we look forward to expanding our franchise further.

* excluding those sub £5m by market capitalisation
** excluding fundraises of sub £5m


Supporting growth strategy

Cavendish has been involved in managing multiple sell downs over recent years and completed two in Q1 2024, realising £11m in aggregate.   

These sell downs, in Bioventix plc and hVIVO plc, were both over subscribed and introduced a number of high quality investors to the register. 

We have an ongoing desire to broaden the shareholder base of all our corporate clients and were pleased to be able to do so for both of these fantastic businesses – we brought Bioventix to AIM with a market cap of £28m (now £230m) and started working with hVIVO (then Open Orphan) in mid 2020 when the market capitalisation was £70m (£190m in early July).

“We were extremely pleased with the sell down and Cavendish out-performed on several levels – they added a number of new high quality investors to the register, at a very slim discount whilst also creating sufficient demand to be over subscribed.   I was delighted with the result and remain confident in the growth prospects for hVIVO as the business continues to execute on its strategy.”

Let’s work together